학술논문
Rapid investigation of BA.4/BA.5 cases in France
Document Type
article
Author
Alain-Claude Kouamen; Helena Da Cruz; Mohamed Hamidouche; Anais Lamy; Anna Lloyd; Javier Castro Alvarez; Mathilde Roussel; Laurence Josset; Vincent Enouf; Charlotte Felici; Georges Dos Santos; Justine Schaeffer; Anna Maisa; Regional COVID-19 Investigation Group; Laboratory Group; Gwenola Picard; Vikpognon Michée Géraud; Alice Brembilla; Ellen Dahl; Souhaila Chent; Alizé Mercier; Gwladys Nadia Gbaguidi; Carine Grenier; Adeline Riondel; Huchet-Kervella Caroline; Bekheira Leila; Kemeny Stephan; Claire Vignault; Pauline Trémeaux; Pierre-Edouard Fournier; Sophie Vallet; Diane Descamps; Lionel Chollet; Nefert Dossou; Alice Moisan; Anais Soares; Marie Christine Jaffar Bandjee; Alexis de Rougement; Cécile Henquell; Anne Lavergne
Source
Frontiers in Public Health, Vol 10 (2022)
Subject
Language
English
ISSN
2296-2565
51444593
51444593
Abstract
AimWe aimed to describe the characteristics of individuals infected by BA.4 or BA.5 in France in comparison to BA.1, and analyze the factors associated with hospitalization among BA.4 and BA.5 cases.MethodsA standardized questionnaire was used to collect information on confirmed and probable Omicron cases. Hospitalization risk factors among BA.4/BA.5 cases were analyzed using Poisson regression. Variables with a p-value below 0.2 in the univariate analysis and a priori confounders were included in the multivariable regression model.ResultsThe median age of the 301 cases investigated was 47 years and 97% of cases were symptomatic. The most common clinical signs were asthenia/fatigue (75.7%), cough (58.3%), fever (58.3%), headache (52.1%) and rhinorrhea (50.7%). Twelve cases were hospitalized, and 27.1% reported risk factors. No admissions to intensive care and no deaths were reported. Vaccination status was available for 292 cases, 20.9% were unvaccinated, 1.4% had received one dose, 38.3% two doses and 39.4% three doses. Cases presenting at least one risk factor were almost seventeen times more likely to be hospitalized than those with no risk factors (aRR = 16.72 [95% CI2.59–326.86]).ConclusionDespite the longer duration of and the differences in symptoms and their possible immune escape, BA.4/BA.5 Omicron sub-lineages globally showed no severe clinical presentation. The presence of at least one risk factor for severe disease significantly increased the risk of hospitalization for those infected with BA.4 or BA.5.